145 related articles for article (PubMed ID: 31103365)
21. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
Awasthi S; Hook LM; Shaw CE; Friedman HM
Hum Vaccin Immunother; 2017 Dec; 13(12):2785-2793. PubMed ID: 28481687
[TBL] [Abstract][Full Text] [Related]
22. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
[TBL] [Abstract][Full Text] [Related]
23. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.
Tronstein E; Johnston C; Huang ML; Selke S; Magaret A; Warren T; Corey L; Wald A
JAMA; 2011 Apr; 305(14):1441-9. PubMed ID: 21486977
[TBL] [Abstract][Full Text] [Related]
24. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.
Agyemang E; Magaret AS; Selke S; Johnston C; Corey L; Wald A
J Infect Dis; 2018 Oct; 218(11):1691-1699. PubMed ID: 30020484
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
26. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.
Leone P; Warren T; Hamed K; Fife K; Wald A
Sex Transm Dis; 2007 Nov; 34(11):900-7. PubMed ID: 17538513
[TBL] [Abstract][Full Text] [Related]
27. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
[TBL] [Abstract][Full Text] [Related]
28. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
[TBL] [Abstract][Full Text] [Related]
29. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
Wald A; Zeh J; Selke S; Warren T; Ryncarz AJ; Ashley R; Krieger JN; Corey L
N Engl J Med; 2000 Mar; 342(12):844-50. PubMed ID: 10727588
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.
Moss NJ; Magaret A; Laing KJ; Kask AS; Wang M; Mark KE; Schiffer JT; Wald A; Koelle DM
J Virol; 2012 Sep; 86(18):9952-63. PubMed ID: 22761381
[TBL] [Abstract][Full Text] [Related]
31. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
[TBL] [Abstract][Full Text] [Related]
32. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
[TBL] [Abstract][Full Text] [Related]
33. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
[TBL] [Abstract][Full Text] [Related]
35. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons.
Wald A; Koelle DM; Fife K; Warren T; Leclair K; Chicz RM; Monks S; Levey DL; Musselli C; Srivastava PK
Vaccine; 2011 Nov; 29(47):8520-9. PubMed ID: 21945262
[TBL] [Abstract][Full Text] [Related]
38. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
Awasthi S; Shaw C; Friedman H
Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
[TBL] [Abstract][Full Text] [Related]
39. Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.
Awasthi S; Onishi M; Lubinski JM; Fowler BT; Naughton AM; Hook LM; Egan KP; Hagiwara M; Shirai S; Sakai A; Nakagawa T; Goto K; Yoshida O; Stephens AJ; Choi G; Cohen GH; Katayama K; Friedman HM
Viruses; 2023 May; 15(5):. PubMed ID: 37243234
[TBL] [Abstract][Full Text] [Related]
40. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
